Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Lung Cancer

Lung Cancer

54 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lung Cancer

318 trials tracked for Lung Cancer: 35 in phase 3 or 4 and 12 with published results. The most-cited published study has 1670 citations.

318Trials tracked
35Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 4 Phase 3 31 Phase 2 165 Phase 1 13 Other / NA 105
  1. Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,670 cited
  2. Phase 3 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Completed · 981 cited
  3. Phase 3 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed · 594 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Completed · 273 cited
  5. Phase 3 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) Completed · 215 cited
  6. Phase 3 Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer Completed · 117 cited
Show 44 more trials
  1. Phase 3 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed · 109 cited
  2. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 94 cited
  3. Phase 4 An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Completed · 72 cited
  4. Phase 3 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed · 71 cited
  5. Phase 3 PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers Completed · 18 cited
  6. Phase 3 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Completed · 11 cited
  7. Phase 4 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed
  8. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  9. Phase 3 Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer Completed
  10. Phase 3 Iressa Follow-up Trial Completed
  11. Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
  12. Phase 3 A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Completed
  13. Phase 3 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting Completed
  14. Phase 3 T790M Plasma Testing Methodology Comparison and Clinical Validation Completed
  15. Phase 3 A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia Completed
  16. Phase 3 A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Completed
  17. Phase 3 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Completed
  18. Phase 3 Bintrafusp Alfa Program Rollover Study Completed
  19. Phase 3 Evaluation of the Bio-Seal Biopsy Track Plug Completed
  20. Phase 3 PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer Completed
  21. Phase 3 National Lung Screening Trial (NLST) Screening Completed
  22. Phase 3 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients Completed
  23. Phase 3 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer Completed
  24. Phase 3 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Completed
  25. Phase 3 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed
  26. Phase 3 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed
  27. Phase 3 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Completed
  28. Phase 3 Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed
  29. Phase 3 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed
  30. Phase 2 Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC) Completed
  31. Phase 2 Study of Arsenic Trioxide in Small Cell Lung Cancer Completed
  32. Phase 2 Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions Completed
  33. Phase 2 BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Completed
  34. Phase 2 Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Completed
  35. Phase 2 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer Completed
  36. Phase 2 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed
  37. Phase 2 Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
  38. Phase 2 Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC Completed
  39. Phase 2 Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer Completed
  40. Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Completed
  41. Phase 2 Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy Completed
  42. Phase 2 BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed
  43. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  44. Phase 2 Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed

Showing the 50 most-cited and recently-updated of 318 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Lung Cancer: what the trials found

Brigatinib demonstrated statistically significant improvements in progression-free survival (PFS) and confirmed objective response rates (ORR) compared to other cohorts 13. Specifically, Brigatinib showed a significant improvement in intracranial ORR 13.

Radiation therapy was associated with significant differences in neurocognitive progression at 3 months, as well as significant differences in local and distant tumor control at 3 months 12.

Cetuximab showed a statistically significant improvement in overall survival (OS) compared to other cohorts 14.

Vorinostat showed a statistically significant improvement in progression-free survival (PFS) 16.

Recent results — preliminary, needs further review

  • * VGT-309 was associated with a statistically significant reduction in Clinically Significant Events (p=<.0001) 1. * Clinical trials are investigating various supportive and diagnostic interventions including Virtual Navigation Systems 2, CBCT Imaging 3, BioSpy System 5, MyLungHealth 6, and Transportation 7. * One fraction stereotactic body radiotherapy is under investigation 4.

For the clinician treating this condition

  • Brigatinib is associated with superior progression-free survival and intracranial response rates 13.
  • Radiation therapy impacts neurocognitive status and tumor control metrics 12.
  • Cetuximab is associated with improved overall survival 14.
  • Vorinostat is associated with improved progression-free survival 16.

AI synthesis of 11 cited trials, updated Sep 9, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pirfenidone reduces lung cancer incidence by 73% in IPF patients with a pooled risk ratio of 0.39
Pulmonology & Critical Care Meta-analysis
Pirfenidone reduces lung cancer incidence by 73% in IPF patients with a pooled risk ratio of 0.39 Antifibrotic drugs may lower lung cancer risk in patients with idiopathic pulmonary fibrosis
This systematic review and meta-analysis evaluated antifibrotic therapies in 15582 patients with idiopathic pulmonary fibrosis. The pooled a…
A large review suggests antifibrotic drugs like pirfenidone might lower lung cancer risk in people with idiopathic pulmonary fibrosis, but m…
Jun 2, 2026
Network meta-analysis ranks nonpharmacological dyspnoea strategies in lung cancer
Oncology Sys. Review
Network meta-analysis ranks nonpharmacological dyspnoea strategies in lung cancer Acupressure and Fan Therapy Ease Breathing in Lung Cancer
This systematic review and network meta-analysis of 4138 lung cancer patients found that acupressure had the highest efficacy for dyspnoea r…
A review of 4138 patients found acupressure most effective for shortness of breath in lung cancer, followed by fan therapy. For post-operati…
May 28, 2026
Systematic Review Maps Exponential Growth of Antibody-Drug Conjugate Trials in Lung Cancer
Oncology Meta-analysis
Systematic Review Maps Exponential Growth of Antibody-Drug Conjugate Trials in Lung Cancer Global review shows antibody-drug conjugates for lung cancer trials are growing fast
This systematic review of 466 global trials documents exponential growth in antibody-drug conjugate (ADC) trials for lung cancer, from 1 in …
A global review of lung cancer trials shows antibody-drug conjugate research is expanding rapidly, with more than 100 new trials registered …
Frontiers May 21, 2026
Systematic review of lung cancer in pregnancy reports treatment patterns and outcomes
Oncology Meta-analysis
Systematic review of lung cancer in pregnancy reports treatment patterns and outcomes Women with lung cancer during pregnancy need careful treatment plans and close medical care for best results
This systematic review synthesized 96 cases of lung cancer diagnosed during pregnancy. It found that 58.9% had actionable driver alterations…
A review of ninety-six cases shows most mothers had advanced cancer when diagnosed. Many received chemotherapy or targeted drugs safely, wit…
Frontiers May 13, 2026
Meta-analysis finds Type 2 diabetes linked to poorer survival in solid tumor patients on immune checkpoint inhibitors
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds Type 2 diabetes linked to poorer survival in solid tumor patients on immune checkpoint inhibitors Patients with diabetes may face worse survival outcomes when treated with certain cancer drugs compared to those without diabetes
This meta-analysis of 1,225 participants with solid tumors treated with immune checkpoint inhibitors found that Type 2 diabetes was associat…
A large review found that people with type 2 diabetes had lower survival rates when using specific cancer medicines. This link was strong in…
Frontiers May 11, 2026
Narrative review of lung, breast, liver, and kidney cancer evidence
Urology Meta-analysis
Narrative review of lung, breast, liver, and kidney cancer evidence New Cancer Tests Could Spot Tumors Years Earlier Than Before
This narrative review synthesizes published English-language evidence on lung, breast, liver, and kidney cancers. The authors note the scope…
A new wave of cancer biomarker tests can spot lung, breast, liver, and kidney tumors years earlier, opening the door to faster treatment and…
Frontiers May 9, 2026
Narrative review of Citri Reticulatae Pericarpium flavonoids in lung cancer microenvironment modulation
Oncology Sys. Review
Narrative review of Citri Reticulatae Pericarpium flavonoids in lung cancer microenvironment modulation Citrus Flavonoids May Help Remodel Tumors And Boost Immune Therapy
This narrative review examines the role of flavonoids from Citri Retrollatae Pericarpium (CRP), including nobiletin, hesperidin, and tangere…
New citrus compounds could reshape the environment around lung cancer cells to help standard treatments work better for patients.
Frontiers May 5, 2026
Systematic review examines tumor microenvironment mechanisms in lung cancer brain metastases
Infectious Disease Sys. Review
Systematic review examines tumor microenvironment mechanisms in lung cancer brain metastases New brain strategies target lung cancer before it spreads
This systematic review explores the complex mechanisms driving brain metastasis in patients with lung cancer.
Doctors are finding clever new ways to fight lung cancer that has spread to the brain without breaking the body's natural barriers
Frontiers Apr 30, 2026
Systematic review and meta-analysis of nurse-led shared decision-making for lung cancer screening uptake
Oncology Meta-analysis
Systematic review and meta-analysis of nurse-led shared decision-making for lung cancer screening uptake Nurse-led conversations may help high-risk lung cancer patients choose low-dose CT scans
This systematic review and meta-analysis evaluates nurse-led shared decision-making in high-risk lung cancer populations.
A review of 13,608 patients found nurse-led shared decision-making increased willingness to participate in lung cancer screening, with most …
Apr 23, 2026
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
Allergy & Immunology Sys. Review
Narrative review discusses immune checkpoint inhibitors in lung cancer patients New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Frontiers Apr 20, 2026
Prophylactic rhG-CSF with platinum chemotherapy improves immune markers and response rates in advanced lung cancer patients
Pulmonology & Critical Care RCT
Prophylactic rhG-CSF with platinum chemotherapy improves immune markers and response rates in advanced lung cancer patients New drug boost may help some advanced lung cancer patients respond better to treatment
This randomized controlled trial enrolled 150 patients with advanced lung cancer at a hospital in Yuhang District.
A new drug boost helps advanced lung cancer patients maintain stronger white blood cell counts and fight infections better during standard c…
Apr 13, 2026
Mindfulness interventions show mixed effects on breathlessness and pulmonary function in lung cancer patients
Pulmonology & Critical Care Meta-analysis
Mindfulness interventions show mixed effects on breathlessness and pulmonary function in lung cancer patients Mindfulness helps lung function and mood in lung cancer patients, but not breathlessness
A meta-analysis of 14 RCTs involving 1,190 lung cancer patients found mindfulness-based interventions did not significantly improve breathle…
Mindfulness improved lung function and mood for cancer patients, but it did not reduce the feeling of breathlessness.
Apr 13, 2026

Questions about Lung Cancer

How is EGFR-mutant lung cancer treated when it causes leptomeningeal metastasis?

For EGFR-mutant lung cancer that has spread to the lining of the brain (leptomeningeal metastasis), studies point to osimertinib, sometimes combined with bevacizumab, and pemetrexed as treatments linked to longer survival.

Full answer →
How well does osimertinib work for lung cancer patients who have active brain metastasis?

Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and intracranial responses, though resistance can develop.

Full answer →
Which method is best for placing fiducial markers before radiation for lung cancer?

Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.

Full answer →
Can a high neutrophil-to-lymphocyte ratio predict if lung cancer will spread to the brain?

Yes, a high neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for brain metastasis in lung cancer, according to a meta-analysis of 14 studies.

Full answer →
What are the risks of brain metastasis in patients diagnosed with lung cancer?

Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor; targeted therapies like osimertinib show high intracranial response rates.

Full answer →
See all 5 questions about Lung Cancer →